skip to Main Content

Expert Discusses Olaparib for BRCA+ Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
In December 2019, the Food and Drug Administration (FDA) approved olaparib (Lynparza) for the frontline maintenance treatment of patients with BRCA-positive pancreatic cancer.

This was a major advancement for this patient subset, explained Teresa Marcarulla, MD, a gastrointestinal medical oncologist at the Vall d’Hebron Institute of Oncology. Watch here. . .


Back To Top